A 35-year-old woman presents with fever, facial edema, and a widespread erythematous maculopapular rash that began 3 weeks after starting carbamazepine for newly diagnosed epilepsy. Laboratory investigations reveal: WBC 12,000/μL with 15% atypical lymphocytes, ALT 180 U/L, AST 165 U/L, and mild lymphadenopathy on examination. Which of the following is the most appropriate immediate management?

Explanation

## DRESS Syndrome: Recognition and Management ### Clinical Presentation This patient presents with the classic triad of **DRESS syndrome** (Drug Reaction with Eosinophilia and Systemic Symptoms): **Key Point:** DRESS is a severe, potentially life-threatening drug reaction characterized by: - Cutaneous manifestations (rash, facial edema) - Systemic involvement (fever, lymphadenopathy, hepatic dysfunction) - Hematologic abnormalities (atypical lymphocytes, eosinophilia) ### Diagnostic Criteria (RegiSCAR Scoring) This case meets criteria for probable to definite DRESS: | Feature | Present in Case | Significance | |---------|-----------------|---------------| | Fever (>38.5°C) | Yes | Core feature | | Rash | Yes (maculopapular, facial edema) | Typical presentation | | Lymphadenopathy | Yes | Systemic involvement | | Atypical lymphocytes | Yes (15%) | Hematologic marker | | Hepatic involvement | Yes (ALT/AST ↑) | Organ involvement | | Temporal relation to drug | Yes (3 weeks post-carbamazepine) | Causative agent identified | **High-Yield:** The **temporal relationship** is critical — DRESS typically develops 2–8 weeks after drug initiation (carbamazepine is a classic culprit). ### Immediate Management Algorithm ```mermaid flowchart TD A[Suspected DRESS Syndrome]:::outcome --> B{Confirm diagnosis<br/>via RegiSCAR criteria}:::decision B -->|Probable or Definite| C[DISCONTINUE offending drug<br/>immediately]:::urgent C --> D[Initiate systemic corticosteroids<br/>Prednisolone 0.5-1 mg/kg/day]:::action D --> E[Monitor liver, CBC, renal function<br/>weekly for 4-6 weeks]:::action E --> F[Taper corticosteroids over<br/>6-12 weeks]:::action F --> G[Clinical and biochemical<br/>resolution]:::outcome B -->|Low probability| H[Reassess diagnosis]:::decision ``` ### Why Option 1 is WRONG **Warning:** Continuing the offending drug while adding corticosteroids is contraindicated. The drug must be withdrawn immediately to prevent progression to: - Fulminant hepatic failure - Disseminated intravascular coagulation (DIC) - Multi-organ failure - Death (mortality 10–15% if untreated) ### Rationale for Correct Answer (Option 2) **Key Point:** The **two pillars** of DRESS management are: 1. **Immediate discontinuation** of the offending drug 2. **Systemic corticosteroids** (prednisolone 0.5–1 mg/kg/day, tapered over 6–12 weeks) **Clinical Pearl:** Early recognition and drug withdrawal are the strongest predictors of favorable outcome. Delaying withdrawal increases risk of hepatic necrosis and systemic complications. **High-Yield:** Carbamazepine is one of the **top 3 culprits** for DRESS (along with allopurinol and sulfonamides). Other aromatic antiepileptics (phenytoin, phenobarbital) carry similar risk. ### Why Option 3 is WRONG Switching to phenytoin does NOT address the acute DRESS reaction. Moreover: - Phenytoin is also an aromatic antiepileptic with **cross-reactivity risk** (up to 80% of patients with carbamazepine-induced DRESS may react to phenytoin) - The acute systemic manifestations (hepatitis, lymphadenopathy, fever) require immediate corticosteroid therapy - Delaying corticosteroid initiation worsens prognosis ### Why Option 4 is WRONG While skin biopsy may show: - Superficial perivascular lymphocytic infiltrate - Interface dermatitis - Eosinophilic infiltration **Warning:** Deferring treatment pending biopsy is dangerous. DRESS is a clinical diagnosis supported by RegiSCAR scoring; histology is confirmatory but NOT required to initiate treatment. The patient is at immediate risk of hepatic failure and systemic deterioration. ### Monitoring During Treatment **Tip:** After drug withdrawal and corticosteroid initiation, monitor: - Liver function tests (ALT, AST, bilirubin) — weekly for 4–6 weeks - Complete blood count (watch for recurrence of atypical lymphocytes) - Renal function - Clinical signs of improvement (rash resolution, fever subsidence) **Clinical Pearl:** Some patients develop **DRESS rebound** (flare of systemic symptoms during corticosteroid taper). This requires temporary dose increase rather than further drug trials. ### Prognosis With appropriate management (drug withdrawal + corticosteroids), most patients achieve complete resolution within 4–12 weeks. Without treatment, mortality approaches 10–15%.